Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting.

Millie D Long,Anita Afzali,Monika Fischer,David Hudesman,Maisa Abdalla,Robert McCabe,Benjamin L Cohen,Ryan C Ungaro, Will Harlan,John Hanson,Gauree Konijeti,Steven Polyak,Timothy Ritter,Bruce Salzberg,Jennifer Seminerio,Emily English,Xian Zhang,Puza P Sharma,Hans H Herfarth

Inflammatory bowel diseases（2023）

引用 7|浏览24

暂无评分

摘要

In this prospective real-world study, tofacitinib resulted in a rapid and persistent improvement in UC disease activity PROs. The safety findings were consistent with the established safety profile of tofacitinib.

查看译文

关键词

patient report outcomes,safety,tofacitinib,ulcerative colitis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要